Kiora Pharmaceuticals, Inc.

KPRX

NASDAQ

Healthcare

Biotechnology

Encinitas, UT, US12 employeeskiorapharma.com

$1.96

+0.01(0.51%)

Mkt Cap $8M

$1.80

$3.90

52-Week Range

At a Glance

AI-generated

Kiora Pharmaceuticals, Inc.

Revenue breakdown: Reportable Segment (100%).

8-K

Kiora Pharmaceuticals announced the resignation of Chief Development Officer Eric J. Daniels effective April 17, 2026, to pursue another opportunity, with the company initiating a search for his successor.

$8M

Market Cap

—

Revenue

-$7M

Net Income

Employees12

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($16M)

Activity

What Changed Recently

Management Change

Apr 1, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1,

Financial Results

Mar 24, 2026

, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Thi

Peer Companies

Company	Price	Change	Market Cap	P/E
PHIOPhio Pharmaceuticals Corp...	$1.27	-1.92%	$15M	-1.7
RNAZTransCode Therapeutics, I...	$8.68	-0.07%	$8M	-0.3
APVOAptevo Therapeutics Inc.	$4.13	-0.97%	$7M	-0.0
BCDABioCardia, Inc.	$1.19	+2.59%	$7M	-0.9
INABIN8bio, Inc.	$1.46	+3.93%	$7M	-0.4
ACXPAcurx Pharmaceuticals, In...	$3.72	-4.37%	$6M	-0.9
CELZCreative Medical Technolo...	$2.05	+3.02%	$5M	-0.7
APREAprea Therapeutics, Inc.	$0.71	+0.34%	$5M	-0.4

Analyst View

Company Profile

CIK0001372514

ISINUS49721T5074

CUSIP49721T101

Phone781 788 8869

Address1371 East 2100 South, Encinitas, UT, 84105, US

SEC EDGAR